SELECTIVE BIFUNCTIONAL DRUG ON THE BASIS OF FRAGMENTS OF CAMEL SINGLE-CHAIN ANTIBODIES, AIMED ON TUMOR RECEPTORS CD47/CD44, INTENDED FOR THERAPY OF MALIGNANT NEOPLASMS

摘要

FIELD: biotechnology.;SUBSTANCE: selective bifunctional protein complex is proposed that suppresses growth and/or causes apoptosis of cancer stem cells, consisting of two fragments of the variable parts of VHH-camel antibodies, capable of recognizing and selectively binding to the CD47 and CD44 cellular receptors, where the fragments are linked together into a single polypeptide chain by a polypeptide linker.;EFFECT: this complex possesses a high specificity, bioavailability, and, in comparison with traditional monoclonal antibodies, highly effective and selectively affects cancer stem cells, while having a minimal effect on the normal cells of the patient's body.;1 cl, 2 ex